Texas MPN Workshop 2022 | The safety and efficacy of avapritinib in patients with advanced systemic mastocytosis
Deepti Radia
• 30 Aug 2022
Deepti Radia, MBBS, BSc, MRCPI, FRCPath, MSc Med Ed, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, shares some insights into the safety and efficacy of avapritinib in patients with advanced systemic mastocytosis, and further highlights results from the PATHFINDER (NCT03580655) and EXPLORER (NCT02561988) trials. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.
Disclosures
Advisory Board and Honoraria: Novartis, Consultant and Honoraria: Blueprint Medicines, Cogent Biosciences.
Study response adjudication committees : EXPLORER/PATHFINDER – Blueprint Medicines and APEX -Cogent Biosciences.
